Instituto de Investigación Sanitaria, ALS Unit

University Hospital 12 de Octubre

The ALS Unit at the Hospital 12 de Octubre in Madrid is one of the 4 ALS Units in the capital district of Spain. It is the only one in the whole country which includes a research laboratory.

University Hospital 12 de Octubre

Our principal aims are to study the genetics of the Spanish ALS population, to discover new prognostic and diagnostic biomarkers, and to develop preclinical and clinical assays.

Contact
Location
University Hospital 12 de Octubre, Avenida de Córdoba, Madrid, Spain
Contact

Our Specialists

Jesús Esteban Pérez

Principal investigator

Dr. Jesús Esteban Pérez is Principal investigator in University Hospital 12 de […]

Jesús Esteban Pérez
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more